This measure assesses the percentage of members 18–64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening during the measurement year.
Why It Matters
People with schizophrenia, schizoaffective disorder or bipolar disorder are at greater risk of metabolic syndrome due to their serious mental illness.1 Diabetes screening is important for anyone with schizophrenia, schizoaffective disorder or bipolar disorder, and the added risk associated with antipsychotic medications contributes to the need to screen for diabetes. Diabetes screening for individuals with schizophrenia, schizoaffective disorder or bipolar disorder prescribed an antipsychotic medication may lead to earlier identification and treatment of diabetes in these groups.
Historical Results – National Averages
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications
| Measurement Year | Medicaid HMO |
|---|---|
| 2023 | 81.3 |
| 2022 | 79 |
| 2021 | 79.2 |
| 2020 | 76.7 |
| 2019 | 81.7 |
| 2018 | 80.6 |
| 2017 | 80.8 |
This State of Healthcare Quality Report classifies health plans differently than NCQA’s Quality Compass. HMO corresponds to All LOBs (excluding PPO and EPO) within Quality Compass. PPO corresponds to PPO and EPO within Quality Compass.
Figures do not account for changes in the underlying measure that could break trending. Contact Information Products via my.ncqa.org for analysis that accounts for trend breaks.
References
- Vancampfort, D., B. Stubbs, A.J. Mitchell, M. De Hert, M. Wampers, P.B. Ward, S. Rosenbaum, and C.U. Correll. 2015. “Risk of Metabolic Syndrome and Its Components in People with Schizophrenia and Related Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review and Meta-Analysis.” World Psychiatry 14 (3): 339–47.